FT. LAUDERDALE, FL--(MARKET WIRE)--Jul 2, 2007 -- OmniComm Systems, Inc. (OTC BB:OMCM.OB - News), one of the fastest growing companies in the EDC marketplace, today announced that it will partner with Pharmatech, Inc., a Research Management Organization (RMO), to build a patient registry database that will improve patient accrual in clinical trials. The database will leverage the data mining functionality inherent in OmniComm’s First in Functionality™ TrialMaster® EDC solution to facilitate the screening and identification of patient candidates for cutting-edge oncology research. OmniComm will be the exclusive choice for Pharmatech and their network physicians who utilize EDC for clinical trials. Pharmatech will begin using TrialMaster in a multi-center, Phase II clinical trial for advanced Non-Small Cell Lung Cancer (NSCLC).
